Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Value Investors Buy Catalyst Pharmaceuticals ( CPRX ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Abivax SA Sponsored ADR ( ABVX ) This Year?
Here is how Abivax SA Sponsored ADR (ABVX) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
Buy These 3 AQR Mutual Funds for Lucrative Returns
Consider investing in AQR mutual funds like QSMNX, AQMNX and AIONX to manage the risk across different market environments.
Santhera Closes USD 13 Million Royalty Monetization Agreement
Pratteln, Switzerland, November 5, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support the global launches of AGAMREE® ( vamorolone ) .
Five-year data of AGAMREE® ( vamorolone ) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
Ad hoc announcement pursuant to Art. 53 LR ...
Five-year data of AGAMREE® ( vamorolone ) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
Pratteln, Switzerland, November 4, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) today reported positive topline results from an analysis of long-term data, including first assessments from the ongoing, open-label, multicenter GUARDIAN study evaluating AGAMREE® ( vamorolone ) in patients with ...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
CORAL GABLES, Fla., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( NASDAQ:CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET ...
Sironax Announces Key Leadership Appointments to Advance Global Drug Discovery and Development
Nasir Khan, DVM, Ph.D.: Senior Vice President of Preclinical Development Gary Ingenito, MD, Ph.D.: Senior Vice President of Clinical Development
What Does the Market Think About Catalyst Pharmaceuticals Inc? - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals Inc's ( NYSE:CPRX ) short interest as a percent of float has risen 11.3% since its last report. According to exchange reported data, there are now 9.63 million shares sold short, which is 10.05% of all regular shares that are available for trading.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Catalyst Pharmaceutical ( CPRX ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
CORAL GABLES, Fla., Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat ...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" ) ( NASDAQ:CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat ...
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® ( Vamorolone ) in Russia
Pratteln, Switzerland, October 9, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® ( vamorolone ) in Russia, for the treatment of Duchenne muscular dystrophy ( DMD ) in patients four years of age and ...
Why Catalyst Pharmaceutical ( CPRX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Santhera Announces Approval in Canada for AGAMREE® ( Vamorolone ) as a Treatment for Duchenne Muscular Dystrophy
Pratteln, Switzerland, October 3, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) today notes that Health Canada has approved AGAMREE® ( vamorolone ) for the treatment of Duchenne muscular dystrophy ( DMD ) in patients aged 4 years and older following Priority Review, marking the first approved ...
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
CORAL GABLES, Fla., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and ...
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
Ad hoc announcement pursuant to Art. 53 LR ...
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR ...
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR ...
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
Ad hoc announcement pursuant to Art. 53 LR ...
Why Catalyst Pharmaceutical ( CPRX ) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceutical ( CPRX ) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How Is The Market Feeling About Catalyst Pharmaceuticals? - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals's CPRX short percent of float has fallen 3.12% since its last report. The company recently reported that it has 8.94 million shares sold short, which is 9.33% of all regular shares that are available for trading.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals President and CEO Trades $473K In Company Stock - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Revealing a significant insider sell on August 28, Richard J Daly, President and CEO at Catalyst Pharmaceuticals CPRX, as per the latest SEC filing. What Happened: Daly's recent Form 4 filing with the U.S. Securities and Exchange Commission on Thursday unveiled the sale of 22,970 shares of ...
Director At Catalyst Pharmaceuticals Sells $525K Of Stock - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
David S Tierney, Director at Catalyst Pharmaceuticals CPRX, executed a substantial insider sell on August 28, according to an SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Tierney sold 26,000 shares of Catalyst Pharmaceuticals.
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® ( Vamorolone ) in India
Pratteln, Switzerland, 29 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Ikris Pharma Network ( Ikris ) to manage the distribution of AGAMREE® ( vamorolone ) in India, for the treatment of Duchenne muscular dystrophy ( DMD ) in patients ...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CORAL GABLES, Fla., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February ...
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend
New York, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- This September, the Muscular Dystrophy Association ( MDA ) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its 75th anniversary.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February ...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® ( Vamorolone ) in five GCC ( Gulf Cooperation Council ) Countries
Pratteln, Switzerland, 19 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® ( vamorolone ) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment ...
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Santhera extends Highbridge convertible bond to 30th September 2025
Ad hoc announcement pursuant to Art. ...
Why Catalyst Pharmaceutical ( CPRX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® ( Vamorolone ) in Türkiye
Pratteln, Switzerland, 13 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. ( GEN ) for the distribution and promotion of AGAMREE® ( vamorolone ) in Türkiye for the treatment of Duchenne ...
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Rigel Pharmaceuticals, Inc. ( RIGL ) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
